Pear Therapeutics

Press Releases

Pear Therapeutics Announces First Patient Dosed in Part II of Pear-006 Feasibility Study to Treat Depressive Symptoms in People with Multiple Sclerosis

Dosing and Patient Engagement to be Evaluated for Novel Prescription Digital Therapeutic
Product Candidate

Boston, December 17, 2019 – Pear Therapeutics, Inc. today announced the first patient dosed in part II of the first clinical study evaluating Pear-006, a digital therapeutic product candidate for addressing depressive symptoms in Multiple Sclerosis (MS). The randomized controlled trial will enroll approximately 30 patients with Relapsing MS for eight weeks treatment with digital therapy and evaluate dosing, patient use, engagement, and other clinical outcomes. Pear-006 is designed to deliver specific cognitive behavioral therapy, cognitive restructuring, and other neurobehavioral mechanisms of action, to address depressive symptoms in people with MS. Pear Therapeutics is developing Pear-006 in collaboration with Novartis under the terms of an agreement announced in March 2018.

“Between 35-50% of people with MS have symptoms of depression[1], yet only inadequate treatment options remain to improve quality of life. Pear Therapeutics understands the importance of not only addressing this unmet need, but doing so in a way that would allow easy access for patients,” said Yuri Maricich, M.D., Chief Medical Officer at Pear Therapeutics. “As pioneers in prescription digital therapeutics, we take pride in leading the first decentralized trial for a digital therapeutic in this patient population, further exploring the potential of this novel therapeutic modality and advancing research for the MS community.”

Prescription digital therapeutics represent a new treatment class in healthcare that blend the iterative design and development agility of software and deliver scientific mechanisms of action which are developed with scientific rigor and evidence-based process required by the FDA for class II A medical devices. Pear-006 has been developed based on valuable insights from patients, scientists and neurologists.

The study began with a part I feasibility study in May 2019, which reported encouraging findings, and further studies on efficacy will be pursued next pending the outcomes of this trial.

About Pear Therapeutics
Pear Therapeutics, Inc. is the leader in prescription digital therapeutics. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurological conditions. Our lead product, reSET®, for the treatment of Substance Use Disorder, was the first prescription digital therapeutic to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of Opioid Use Disorder, received marketing authorization from the FDA in December 2018. For more information, visit us at www.peartherapeutics.com.

Media and Investors:
Meara Murphy
meara.murphy@peartherapeutics.com

 

 

[1] “Prevalence of depression and anxiety in multiple sclerosis: A systematic review and meta-analysis,” https://www.ncbi.nlm.nih.gov/pubmed/28017241

 

Back